Compare Campbell Soup Co. (CPB) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Danaher Corporation — how do they compare? Campbell Soup Co. trades at $19.38 (market cap $5.64B), while Danaher Corporation trades at $217.88 (market cap $153.60B). The key difference: Danaher Corporation is far larger — about 27.2× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.29%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Danaher Corporation for 69 Days on average.
| CPB | DHR | |
|---|---|---|
Market Cap | $5.64B | $153.60B |
Volume | 8,200,811 | 3,974,063 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $242.05 |
52-Week Low | $18.90 | $161.91 |
Typical Hold Time | 98 Days | 69 Days |
Enterprise Value | $12.70B | $175.81B |
Dividend Yield | 5.29% | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical indicators. The company faces margin compression with net income margin at 4.14% and recently cut its dividend by 36% to strengthen the balance sheet. Revenue grew to $10.25B in 2025 but profitability remains under pressure. Analyst consensus shows cautious sentiment with 55% hold ratings and a $19.67 price target.
The outlook remains challenging with weak FY2027 guidance and ongoing restructuring. The $500 million cost savings program and Rao's brand growth offer potential upside, but investors face risks from declining sales, margin pressure, and competitive headwinds in the packaged foods sector.
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
